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Kidney transplant recipients (KTRs) have an increased cancer risk com-
pared to the general population, but absolute risks that better reflect the
clinical impact of cancer are seldom estimated. All KTRs in Sweden, Nor-
way, Denmark, and Finland, with a first transplantation between 1995 and
2011, were identified through national registries. Post-transplantation can-
cer occurrence was assessed through linkage with cancer registries. We esti-
mated standardized incidence ratios (SIR), absolute excess risks (AER),
and cumulative incidence of cancer in the presence of competing risks.
Overall, 12 984 KTRs developed 2215 cancers. The incidence rate of cancer
overall was threefold increased (SIR 3.3, 95% confidence interval [CI]: 3.2–
3.4). The AER of any cancer was 1560 cases (95% CI: 1468–1656) per
100 000 person-years. The highest AERs were observed for nonmelanoma
skin cancer (838, 95% CI: 778–901), non-Hodgkin lymphoma (145, 95%
CI: 119–174), lung cancer (126, 95% CI: 98.2–149), and kidney cancer
(122, 95% CI: 98.0–149). The five- and ten-year cumulative incidence of
any cancer was 8.1% (95% CI: 7.6–8.6%) and 16.8% (95% CI: 16.0–
17.6%), respectively. Excess cancer risks were observed among Nordic
KTRs for a wide range of cancers. Overall, 1 in 6 patients developed cancer
within ten years, supporting extensive post-transplantation cancer vigi-
lance.
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Kidney transplantation has been performed regularly as
treatment for end-stage renal disease in the Nordic
countries since 1964 [1]. Over time, with the introduc-
tion of more efficient immunosuppressive regimens and
advances in both surgical techniques and immunosup-
pressive treatment strategies, patient survival has greatly
improved [2,3]. However, as transplantation-related
mortality has decreased, the incidence of post-transplant
morbidities, such as cancer, has received more attention.
Numerous studies demonstrate a twofold to fourfold
increased risk of developing cancer post-transplantation
compared to the general population [4-18]. Increased
risks have been noted especially for cancer types associ-
ated with infectious agents, similar to in other immuno-
suppressive states such as HIV/AIDS [19].
Despite the well-known increased risks of cancer
among kidney transplant recipients, few studies have
estimated absolute risks of cancer overall and of specific
cancer types post-transplantation with account for com-
peting events [11,16,20]. Absolute overall and excess
risks can facilitate the understanding of the clinical
impact of this serious complication and provide a useful
basis for planning of health care and clinical follow-up
[21]. Furthermore, although nonmelanoma skin cancer
(NMSC) has been shown to be the by far most com-
mon cancer after transplantation, few studies have esti-
mated the relative and absolute risks of all cancer
including NMSC in transplant recipients [7,8].
The aims of this study were therefore to assess rela-
tive and absolute post-transplantation cancer risks
among kidney transplant recipients (KTRs) in the Nor-
dic countries in the modern treatment era, to further
guide monitoring and follow-up of these patients.
Methods
Study population and data sources
All Nordic residents who underwent their first kidney
transplantation during 1995 through 2011 were selected
using national personal identity numbers, from national
inpatient registries (Sweden, Denmark), the Norwegian
Renal Registry, and transplantation clinic registries
(Norway, Finland). Data from the Swedish Renal Regis-
try and from ScandiaTransplant (an organ exchange
organization owned by participating hospitals in Swe-
den, Denmark, Finland, Norway, Iceland, and Estonia)
were further linked to the patient cohort. ScandiaTrans-
plant data were used to establish graft functional status
and donor vital status. Information about cancer occur-
ring after transplantation as well as dates and causes of
death were added from national cancer and cause-of-
death registries. For all countries in the study, reporting
of cancer (including of NMSC) is mandated by law and
registration is close to complete (94-98%) [22]. Start of
follow-up was set to 30 days after the date of the first
transplantation, in accordance with previous studies
[8,11,16] and exit date was date of first post-transplan-
tation cancer diagnosis of each single cancer type by
anatomic location (Table S1), date of death, or end of
follow-up (December 31st of 2011 for Sweden and Den-
mark, 2013 for Finland, and 2014 for Norway), which-
ever came first. Patients were not excluded based on
previous cancer history. However, patients with a pre-
transplantation cancer diagnosis were not followed for
post-transplantation risk of that particular cancer type.
Any cancers diagnosed within 30 days of transplantation
were considered likely present but undiagnosed during
transplantation, which was the rationale for starting fol-
low-up 30 days after the date of first transplantation.
We used the publicly available NORDCAN database
[23], maintained by the Association of the Nordic Can-
cer Registries, to obtain data on the number of expected
cancer cases stratified by country, age at diagnosis, sex,
and calendar period (ICD-10 [International Statistical
Classification of Diseases and Related Health Problems,
tenth revision] codes in Table S1).
The study was approved by The Regional Ethics
Review Boards in Stockholm, Sweden (approval no.
2007/1485-31, 2008/452-39, and 2013/2239-32); the
Regional Committee for Medical Research Ethics—
South East Norway, Oslo (approval no. 2011/1587/REK
sør-øst D); and the Research ethics committee of the
Faculty of Medicine, Helsinki (approval no. 117/13/03/
00/2014). In accordance with national guidelines, we
did not seek an ethics approval in Denmark as the
study only included de-personalized data and no indi-
vidual results are presented, assuring the personal integ-
rity of study persons.
Outcome
The primary outcome was a first cancer diagnosis of
each single cancer type post-transplantation. We
assessed risk of cancer overall and risk of 36 separate
cancer types (Table S1). We also assessed risk of cancer
types known or suspected to be infection-related versus
cancer types regarded as noninfection-related, in line
with previous studies (Table S1) [10,13,19]. NMSC and
cancers of the lip, female genitals (uterine cervix, vulva,
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vagina), male genitals, ear–nose–throat region, stomach,
esophagus, liver and eye, and non-Hodgkin and Hodg-
kin lymphoma were considered infection-related. Can-
cers of the kidney, thyroid, gallbladder, lung, pleura,
bone and soft tissues, colon, small intestine, bladder
and urinary organs unspecified, pancreas, testis, uterus
except cervix, central nervous system (CNS), rectum
and anus (grouped together in NORDCAN), breast,
prostate, ovaries and uterine adnexa, and leukemia, mel-
anoma, and multiple myeloma were considered nonin-
fection-related. We did not perform analyses for basal
cell skin cancers as these cancers are not included in
NORDCAN.
Statistical analyses
Observed numbers of cancer cases were calculated by
country, sex, age group in five-year intervals up to
85 + years (0–4, 5–9,..., 80–84, 85+), and calendar year
and compared to corresponding numbers of expected
cancer in the NORDCAN database to produce stan-
dardized incidence ratios (SIRs). Absolute excess risks
(AER) of cancer were estimated using the same source
data by calculating the difference between observed and
expected number of cancers divided by person-time at
risk. Confidence intervals were calculated using an exact
method assuming a Poisson distribution for the excess
events.
Cox regression models were used to estimate hazard
ratios (HR) and 95% confidence intervals (CI) compar-
ing the rate of cancer by several patient- and transplan-
tation-related factors to identify factors associated with
an excess cancer risk. The model included sex, age at
transplantation (0–49, 50–59 or 60 + years), calendar
period of transplantation (1995–99, 2000–05, 2006–11),
donor vital status (alive/dead), ongoing dialysis (time-
varying exposure categorized as yes/no, with ongoing
dialysis indicating loss of graft [function]), underlying
kidney disease, and history of cancer before transplanta-
tion. The Grambsch–Therneau test on the Schoenfield
residuals was used to test the proportional hazards
assumption [24]. As a sensitivity analysis, to assess the
impact of the functional form of the possible confound-
ing effect of age at transplantation, we also re-fitted the
aforementioned Cox regression model with a restricted
cubic spline with four degrees of freedom (knots at the
20th, 40th, 60th, and 80th percentiles of the age distri-
bution) to represent the age association.
The cumulative incidence (i.e., probability of being
diagnosed with cancer post-transplantation) was subse-
quently calculated in the presence of the competing risk
of death. This measure was computed using numerical
integration of postestimation results (approximation of
baseline hazard and the linear predictor) from the above
Cox regression model, as described in a tutorial paper
by Putter et al. [25]. Confidence intervals were obtained
using bootstrapping. Separate models were fitted to esti-
mate risk of any cancer (unadjusted), risk of any cancer
and infection/noninfection-related cancer stratified by
sex and age, and temporal trends in cumulative inci-
dence stratified by sex and age. Additionally, we
assessed the cumulative incidence of colorectal, lung,
prostate, breast, kidney cancer, NMSC, and non-Hodg-
kin lymphoma (NHL) separately.
SAS version 9.4 (Copyright © 2002-2012 by SAS
Institute Inc., Cary, NC, USA) and STATA version 13
(StataCorp. 2013. Stata Statistical Software: Release 13.
College Station, TX: StataCorp LP.) were used to per-
form the analyses.
Results
In the combined cohort, 12 984 KTRs (4723 Swedish,
3156 Norwegian, 2629 Finnish, and 2476 Danish) were
included, with a median age of 50 years (range 0–83) at
transplantation (Table 1). The total follow-up time was
98 745 years (median 7.0 years, range 0–20). Two thirds
of KTRs were male, and the age distribution was similar
by country, except that Norwegian KTRs were some-
what older at transplantation (median 54 years), and
Danish KTRs younger (median 46 years) (Table 1).
During post-transplantation follow-up, 2215 cancers
were diagnosed in 1845 KTRs, translating to a crude
incidence of 2243 cancers per 100 000 person-years.
NMSC was most common, accounting for 34% of all
cancer cases, followed by lung cancer (7.6%), prostate
cancer (7.0%), NHL (6.6%), kidney cancer (5.5%),
malignant melanoma (3.9%), and colon cancer (3.9%).
Only 3 cases of Kaposi’s sarcoma were observed, all of
which were located in the skin, and thus classified as
NMSC (Table S1).
Risk factors for cancer
Female KTRs had a 27% lower rate of cancer compared
to male (HR: 0.73, 95% CI: 0.66–0.81), and the rate of
cancer increased with age at transplantation (Table 2).
Neither ongoing dialysis, donor vital status, nor under-
lying kidney disease was associated with post-transplan-
tation cancer risk; however, a history of cancer before
transplantation was associated with a 36% increased rate
of post-transplantation cancer (Table 2). The
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proportional hazards assumption was not violated. In
the sensitivity analysis, modeling age at transplantation
using a spline instead of a categorical variable did not
materially change the results (Table S2 and Figure S1).
Relative risks
We found a 3.3-fold increased risk of cancer overall in
KTRs (SIR: 3.29, 95% CI: 3.15–3.43), and a 2.2-fold
increased risk when excluding NMSC (SIR: 2.22, 95%
CI: 2.11–2.34), compared to the general population
(Fig. 1). In all four countries, the SIRs of cancer overall
ranged from approximately 3 to 4 (Sweden, SIR: 2.98,
95% CI: 2.75–3.23; Norway, SIR: 3.39, 95% CI: 3.16–
3.63; Denmark, SIR: 3.73, 95% CI: 3.35–4.15; Finland,
SIR: 3.27, 95% CI: 2.97–3.59; Table S3 and Figure S2).
However, the background cancer incidence rates differ
between the four countries with lower rates in Sweden
and Finland (Figure S3). There was an overall 11-fold
increased risk of infection-related cancer in KTRs (SIR:
11.4, 95% CI: 10.7–12.1; Fig. 1). Among infection-re-
lated cancers, elevated risks were found for NMSC, lip,
vulva and vaginal cancer, NHL, penile, and nasal/sinu-
soidal cancer, Hodgkin lymphoma, oral cavity, liver,
cervical, and stomach cancer. When excluding NMSC,
the risk of infection-related cancer was fourfold
increased (SIR: 4.18, 95% CI: 3.72–4.67). The risk of
noninfection-related cancer was twofold increased (SIR:
1.97, 95% CI: 1.86–2.09). Among these, we found ele-
vated risks of kidney, thyroid, other specified, lung,
unknown and ill-defined, gallbladder, pleural, colon,
small intestine, bladder/urothelial, bone/soft tissue, pan-
creatic, and uterine (except cervical) cancer, as well as
malignant melanoma and multiple myeloma.
Absolute excess risks and cumulative incidence
The AER of any cancer was 1560 cases per 100 000 per-
son-years (95% CI 1468–1656) (Fig. 1). About half of the
excess cancer risk was because of NMSC (AER: 838, 95%
CI 778–901). Apart from NMSC, the cancer forms con-
tributing most to the excess cancer risk were NHL (AER:
145, 95% CI 119–174), lung cancer (AER: 126, 95% CI
98.2–157), kidney cancer (AER: 122, 95% CI 98.0–149),
melanoma (AER: 66.4, 95% CI 46.6–89.6), and colon
cancer (AER: 53.1, 95% CI 33.4–76.2). The cumulative
incidence of cancer overall increased with age and was
higher among men than among women (Fig. 2). The
five-year cumulative incidence of cancer including NMSC
was 8.1% (95% CI: 7.6–8.6%) overall, 8.9% (95% CI:
8.3–9.6%) among male, and 6.5% (95% CI: 6.0–7.2%)
among female KTRs (Fig. 2). Excluding NMSC, the five-
year cumulative incidence was 4.9% (95% CI: 4.5–5.4%)
overall, 5.2% (95% CI: 4.8–5.7%) among male and 4.4%
(95% CI: 3.9–5.0%) among female KTRs. The cumulative
incidence of infection-related cancer among female KTRs
was comparable to that of noninfection-related cancer in
all age groups, while among older men (60 + years at
transplantation), the absolute risk of infection-related
cancer was higher than that of noninfection-related
Table 1. Distribution of sex, year of and age at 1st transplantation, and median age at 1st transplantation among
Nordic kidney transplant recipients 1995–2011
Characteristics
Sweden Norway Denmark Finland Total
No. (%) No. (%) No. (%) No. (%) No. (%)
No. of patients 4723 (100) 3156 (100) 2476 (100) 2629 (100) 12 984 (100)
Sex
Male 3026 (64) 2119 (67) 1533 (62) 1677 (64) 8355 (64)
Female 1697 (36) 1037 (33) 943 (38) 952 (36) 4629 (36)
Year of 1st Tx
1995–1999 1213 (25) 784 (25) 646 (26) 721 (27) 3364 (26)
2000–2005 1632 (35) 1100 (35) 829 (33) 949 (36) 4510 (35)
2006–2011 1878 (40) 1272 (40) 1001 (40) 959 (36) 5110 (39)
Age at 1st Tx, years
0–18 229 (5) 133 (4) 161 (7) 155 (6) 678 (5)
19–49 2140 (45) 1138 (36) 1312 (53) 1181 (45) 5771 (44)
50–59 1284 (27) 709 (22) 634 (26) 730 (28) 3357 (26)
60–69 970 (21) 751 (24) 343 (14) 479 (18) 2543 (20)
70 + 100 (2) 425 (13) 26 (1) 84 (3) 635 (5)
Median 49 54 46 49 50
No, number. Tx, transplantation.
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cancer (Fig. 3, Table S4). However, upon exclusion of
NMSC (constituting the majority of all infection-related
cancers), the five- and ten-year cumulative incidence of
infection-related cancers were less than half of the risks of
noninfection-related cancers among both men and
women (Fig. 3, Table S4). After NMSC, NHL was associ-
ated with the highest cumulative incidence after five years
among men aged < 50 years at transplantation (Fig-
ure S4 and Table S4). Among men aged 50 + years at
transplantation, prostate cancer and then lung cancer
were the most common cancers after NMSC. Among
women, breast cancer was the most common cancer after
NMSC regardless of age.
The cumulative incidence of cancer over calendar time
increased significantly among men, but not among
women, during the study period (Figure S5). The five-
year absolute cancer risks for the periods 1995–1999,
2000–2005, and 2006–2011 were 7.9%, 8.5%, and 10.4%
among males and 6.0%, 6.1%, and 7.4% among females.
However, the overall competing risk of death as first event
declined over calendar time. For the aforementioned cal-
endar periods, the five-year probabilities of death as first
event among men were 10.2%, 8.0% and 7.9% and
among women 10.1%, 7.2%, and 4.5%, respectively.
Discussion
With this population-based study on cancer risk after
kidney transplantation in Sweden, Norway, Denmark,
and Finland in the modern treatment era, we confirm a
3.3-fold elevated risk of developing any primary cancer
after transplantation compared to the general popula-
tion, and a 2.2-fold risk of any cancer excluding NMSC.
Incidence rates of a broad range of both infection-re-
lated and noninfection-related cancers were significantly
increased. The cumulative incidence of cancer overall
Table 2. Cox regression multivariable analysis of risk factors for first post-transplantation cancer (1845 events) among
12 984 Nordic kidney transplant recipients 1995–2014
Characteristics Events HR 95% CI P-value
Sex
Male 1306 Ref Ref
Female 539 0.73 0.66–0.81 <0.001
Age at 1st Tx (years)
0–49 487 0.33 0.29–0.37 <0.001
50–59 596 Ref Ref
60–69 596 1.77 1.58–1.99 <0.001
70+ 166 2.42 2.01–2.91 <0.001
Year of 1st Tx
1995–1999 761 Ref Ref
2000–2005 713 0.89 0.79–0.99 0.03
2006–2011 371 0.95 0.82–1.09 0.47
Dialysis
No 1680 Ref Ref
Yes 165 1.01 0.83–1.23 0.92
Living donor
No 1377 Ref Ref
Yes 439 0.95 0.84–1.06 0.37
Missing 29 0.68 0.46–0.99 0.04
Underlying kidney disease
Kidney failure, NOS 397 Ref Ref
Diabetes 135 0.87 0.71–1.07 0.19
Immunological/inflammatory diseases* 93 0.96 0.76–1.20 0.70
Hypertension 205 1.17 0.98–1.39 0.09
Glomerular and tubulo-interstitial diseases 659 1.06 0.93–1.20 0.41
Malformations and cystic kidney diseases 356 0.97 0.84–1.12 0.68
History of cancer before Tx
No 1699 Ref Ref
Yes 146 1.36 1.14–1.62 <0.001
*For example, Henoch-Sch€onlein’s purpura, hemolytic uremic syndrome. Abbreviations: HR, hazard ratio. CI, confidence inter-
val. Ref, reference group. Tx, transplantation. NOS, not otherwise specified.
1704 Transplant International 2020; 33: 1700–1710
ª 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT
Benoni et al.
was 8% five years after transplantation and 17% after
ten years. The absolute excess risk was 1560 cancer cases
per 100 000 person-years, half of which were because of
NMSC. Other cancer types with high excess risks in
absolute terms were NHL, lung cancer, kidney cancer,
melanoma, and colon cancer.
AERs have seldom been estimated in the previous liter-
ature on cancer risk among KTRs. In the large US study
by Engels et al. [13], AERs were determined in a cohort
of kidney, heart, lung, and liver transplant recipients, but
were not presented for kidney transplant recipients sepa-
rately, and the excess risk of NMSC was not assessed. In a
recent Taiwanese study by Tsai et al. [26], with a follow-
up period similar to our study, the AER was 770 per
100 000 person-years, almost half of which was
accounted for by bladder cancer (AER: 330). As in the
present study, the Taiwanese study also reported AERs
for, for example, lung cancer (AER: 14.8), kidney cancer
(AER: 41.5), and malignant melanoma (AER: 3.8). In
contrast to our results, the AER in Taiwan was negative
for colorectal cancer (AER: 18.6) and cervical cancer
(AER: 33.4), and modest for NMSC (AER: 11.0).
In the present study, NMSC accounted for half of the
excess cancer risk among KTRs. High excess risks also
pertained to one other infection-related cancer type
(NHL) but mostly to more common noninfection-re-
lated cancers (cancer of the lung, kidney and colon, and
melanoma). From a clinical perspective, the excess risks
are more important than relative risks since they reflect
the excess number of cases generated by the transplanta-
tion procedure and associated diseases, and thus to a
larger extent indicate which types of cancers that will
occur among KTRs during clinical follow-up.
Previous reports of relative cancer risks among KTRs
compared to the general population from the most
recent decades demonstrate SIRs of any cancer ranging
from 2.9 to 6.5; and, excluding NMSC, from 2.1 to 3.2
[7,8,10-18]. Hence, our relative risk results are well in
line with previous literature in this regard. The risk of
NMSC was 36-fold compared to the general population.
Other studies have found markedly elevated incidence
of NMSC, ranging from a 7 to 121 times higher risk
than in the general population, with the lowest SIRs for
NMSC found in Asian studies [14,15].
Other cancers that have previously been consistently
associated with increased risk are Hodgkin lymphoma
(SIRs in previous studies 2.4–7.4) and NHL (3.3–16),
malignant melanoma (1.8–9.1), multiple myeloma (1.8–
SIR (95% CI) AER1 (95% CI)
11.4 (10.7 - 12.1) 991 (927 - 1058)
35.9 (33.4 - 38.5) 838 (778 - 901)
26.7 (19.7 - 36.1) 46.0 (32.6 - 62.8)
8.79 (4.99 - 15.5) 33.2 (15.1 - 61.2)
7.59 (6.46 - 8.92) 145 (119 - 174)
6.22 (3.11 - 12.4) 12.0 (3.89 - 26.0)
3.87 (1.45 - 10.3) 3.38 (0.06 - 10.5)
2.68 (1.21 - 5.98) 4.29 (–0.04 - 12.3)
2.32 (1.61 - 3.33) 18.8 (7.86 - 33.2)
2.29 (1.35 - 3.86) 8.98 (1.74 - 19.8)
2.19 (1.14 - 4.20) 15.3 (–0.01 - 40.5)
1.75 (1.13 - 2.71) 9.74 (0.87 - 22.2)
1.49 (0.67 - 3.33) 2.26 (–2.07 - 10.3)
1.39 (0.72 - 2.67) 2.88 (–2.69 - 12.1)
0.69 (0.48 - 4.86) –0.52 (–1.64 - 4.69)
1.97 (1.86 - 2.09) 569 (503 - 638)
7.65 (6.41 - 9.13) 122 (98.0 - 149)
4.24 (2.79 - 6.44) 19.2 (9.80 - 32.0)
3.11 (1.40 - 6.93) 4.65 (0.31 - 12.7)
2.97 (2.41 - 3.66) 66.4 (46.6 - 89.6)
2.88 (2.48 - 3.34) 126 (98.2 - 157)
2.72 (1.93 - 3.83) 23.8 (12.1 - 39.0)
2.56 (1.33 - 4.93) 6.26 (0.69 - 15.5)
2.47 (1.56 - 3.92) 12.2 (3.85 - 24.1)
2.37 (0.99 - 5.70) 3.30 (–0.55 - 10.9)
2.16 (1.75 - 2.66) 53.1 (33.4 - 76.2)
2.13 (0.96 - 4.75) 3.63 (–0.70 - 11.7)
2.12 (1.65 - 2.71) 37.8 (21.2 - 57.9)
2.05 (1.07 - 3.95) 5.27 (–0.30 - 14.5)
1.93 (1.34 - 2.78) 16.0 (5.03 - 30.4)
1.88 (1.25 - 2.83) 12.3 (2.65 - 25.4)
1.74 (0.87 - 3.49) 6.13 (–2.03 - 20.1)
1.41 (0.88 - 2.27) 5.68 (–2.42 - 17.3)
1.30 (0.94 - 1.82) 9.28 (–2.82 - 24.9)
1.27 (0.87 - 1.85) 6.57 (–3.92 - 20.6)
1.17 (1.00 - 1.36) 39.5 (–2.43 - 86.8)
1.16 (0.93 - 1.46) 11.9 (–6.17 - 33.5)
0.88 (0.48 - 1.85) –2.96 (–16.1 - 20.2)
3.29 (3.15 - 3.43) 1560 (1468 - 1656)
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Figure 1 Standardized incidence ratios and absolute excess risks of cancer overall, specific cancer sites and infection- and noninfection-related
cancers among Nordic kidney transplant recipients 1995–2014 compared to the general population. 1AER denotes absolute excess risk per
100.000 person-years. Abbreviations: SIR, standardized incidence ratio. CI, confidence interval. AER, absolute excess risk. NMSC, nonmelanoma
skin cancer. NOS, not otherwise specified. CNS, central nervous system.
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3.9), and cancers of the bladder (1.5–43), colorectum
(1.2–1.8), oral cavity (2.0–5.5), lip (17–66), lung (1.4–
4.8), kidney (4.7–44), liver (2.4–12), thyroid (2.4–8.1),
and vulva/vagina (5.5–21) [7,8,11-18]. Most of these
cancer types were associated with similarly increased
risks among KTRs in our study. The most common
cancers in the general population, prostate cancer
(among men) and breast cancer (among women), were
not associated with an increased risk among KTRs, con-
sistent with previous research.
A handful of previous studies have determined
cumulative incidence of any cancer among KTRs, out of
which a few also accounted for competing events
[11,16,20]. Accounting for the competing risk of death
provides a risk estimation that is applicable to the real
world, that is, where death is a plausible alternative out-
come. These studies demonstrated five-year absolute
cancer risks of 4.4%, 4%, and 1.8% excluding NMSC.
We present a five-year absolute risk excluding NMSC of
4.9%, which is slightly higher than two of the aforemen-
tioned studies, although we did not consider graft
failure and re-transplantation (in contrast to Hall et al.
[20]) or diagnosis of another cancer (in contrast to Vil-
leneuve et al. [11]) as competing events, which might
explain some of the difference. Furthermore, for lung
cancer, we found similar 5-year absolute risks among all
three age groups (up to 50, 50–59, or over 60 years at
transplantation), compared to Hall et al. [20] For kid-
ney and prostate cancer, we found lower absolute risks
among KTRs aged up to 60 years at transplantation,
but higher among KTRs aged over 60 at transplantation.
Finally, for NHL, colorectal, and breast cancer, we
found overall higher risks of cancer among all age
groups. These differences may be because of differing
population rates and definitions of competing events.
The strongest risk factor for cancer in our study was
age, with KTRs aged 70 + years at transplantation hav-
ing a 2.4 times higher rate of cancer than KTRs aged
50–59 years. Also, female sex was associated with a
reduced risk, and cancer history prior to transplantation
with an increased risk, of new primary malignancy. This






































































































Cancer 95 % confidence interval
Figure 2 Five- and ten-year cumulative incidence* of cancer among Nordic kidney transplant recipients 1995–2014, stratified by sex and age
at transplantation. Abbreviations: Tx, transplantation. * Cumulative incidence is estimated in the presence of the competing risk of death.
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factors associated with a higher rate of incident cancer
also in the general population. The same Cox regression
model yielded no significant time trends in cancer rates
by year of transplantation, although the cumulative
incidence of death as a competing event declined over
time. Also, neither time on dialysis (as a measure of lost
graft function), donor vital status, nor underlying kid-
ney disease modified the cancer rates. However, previ-
ous studies have shown a lower rate of cancer among
KTRs with diabetes, compared to among those with
other primary renal diseases [27].
Several cancer-promoting features have been associ-
ated with immunosuppression, such as an impaired
anti-tumor response, impaired ability to counter infec-
tions, carcinogenic features of the medication itself, and
increased susceptibility to damaging effects of ultraviolet
radiation [19,28]. In terms of infection-related carcino-
genesis, an array of different mechanisms has been iden-
tified, including, for example, transfer and integration
of oncogenes between viruses and host cells, (virus-
induced) immunosuppression activating (other) tumor
viruses, chronic inflammation, prevention of apoptosis,
and promotion of chromosomal instability [29].
In our study, infection-related cancers in particular
were associated with an increased risk among KTRs, but
our absolute risk analyses showed that these cancer types
(except NMSC and NHL) were in fact uncommon com-
pared to noninfection-related ones. This suggests that
noninfection-related cancers (and skin cancers and lym-
phoma) should be in focus when constructing screening
protocols for KTRs. In a recent systematic review [30]
Acuna et al. concluded that there is wide support for
screening for skin cancer and for cancers that are already
included in screening programs for the general popula-
tion (e.g., breast and cervical cancer) or for which screen-
ing is recommended (e.g., colorectal, lung [among
present and former smokers], and prostate cancer). For
other cancers, recommendations are conflicting.
Our findings support the use of established and rec-

























































Age <50 years at Tx Age 50-59 years at Tx Age 60+ years at Tx
Figure 3 Five- and ten-year cumulative incidence* of infection-related cancers, with and without inclusion of nonmelanoma skin cancer, and
noninfection-related cancers among Nordic kidney transplant recipients 1995–2014, stratified by sex and age at transplantation. Abbreviations:
Tx, transplantation. NMSC, nonmelanoma skin cancer. * Cumulative incidence is estimated in the presence of the competing risk of death.
Transplant International 2020; 33: 1700–1710 1707
ª 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT
Cancer risks among Nordic kidney transplant recipients
population, although structured clinical follow-up for
early detection of a few other cancer forms (such as
lymphoma) is also warranted. Recent guidelines recom-
mend close follow-up of recipients seronegative for
Epstein–Barr virus (i.e., the majority of children) who
receive an organ from a seropositive donor [31] because
of risk of lymphoma, but otherwise lymphoma-specific
follow-up guidelines are lacking. As post-transplantation
cancer treatment is complicated by possible nephrotoxi-
city and interaction with immunosuppressive treatment,
as well as comorbidities preventing surgical cancer treat-
ment, organ transplant recipients could also benefit
from earlier or extended screening for some cancers for
which screening is not worthwhile in the general popu-
lation.
Strengths of this study include the population-based
design and inclusion of KTRs from four Nordic coun-
tries and the use of national registries with virtually
complete coverage. However, the study also has several
limitations. Firstly, we obtained background cancer rates
from NORDCAN, whereby we also accepted its catego-
rization of cancers. For example, Kaposi’s sarcoma is
categorized by anatomic location both in the NMSC,
bone/soft tissues, and other specified cancers groups;
however, all three cases in our study were found in the
NMSC group. Also, anal cancer (typically virus-related)
is grouped together with rectal cancer (typically non-
virus-related) in NORDCAN and thus could not be
studied separately. Secondly, our study might have
underestimated the overall cancer risks to some extent,
as patients were followed only until first cancer of each
type. Subsequent cancers of the same organ system,
probably more common in KTRs than in the popula-
tion, have therefore been missed. Moreover, for a few
cancer types (e.g., bladder/urothelial cancers), registra-
tion and classification can differ between the national
cancer registers concerned [22], which could possibly
influence risk estimates. Lastly, our findings must be
interpreted within the limitations of grouped observa-
tional data. The presented absolute excess risks are thus
not necessarily applicable to individual patients as there
are a number of additional important factors, such as
smoking status, obesity, and genetic predisposition that
determines the individual risk of being diagnosed with
cancer.
Conclusion
With improving graft and patient survival after solid
organ transplantation, cancer has become an increas-
ingly large threat to organ transplant recipients. This
study confirms previous results of relatively higher can-
cer incidence among KTRs compared to the general
population and adds insight into absolute cancer risks
reflecting the clinical impact. In particular, we observe
high excess risks of specific infection-related (NMSC,
lymphoma) and noninfection-related cancers (lung, kid-
ney). Overall, one in 12 KTRs developed any cancer
over five years following transplantation, and one in 6
over ten years. Our results support screening for NMSC,
and adherence to established screening programs for
common cancers in the general population, with the
addition of clinical vigilance for lymphoma. Further
research should aim to determine the feasibility and
outcomes of structured cancer screening programs for
KTRs using prospective study designs and taking views
from both patients and health care into account.
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